Branchiooculofacial Syndrome

1. Disease Information

1.1 Overview / definition (current understanding)

BOFS is a rare, multisystem congenital craniofacial developmental disorder classically involving branchial cutaneous defects, ocular anomalies, and craniofacial anomalies (especially clefting) (milunsky2008tfap2amutationsresult pages 1-2, min2020aheterozygousnovel pages 1-2). Recent curated summary text notes that “Most individuals with branchiooculofacial syndrome (BOFS) can be diagnosed in infancy on the basis of their clinical features.” (haldemanenglert2025branchiooculofacialsyndrome pages 4-7).

A concise definition from a molecularly confirmed family report states BOFS is “a rare autosomal dominant disorder characterized by craniofacial, ocular, and ectodermal anomalies” (Human Genome Variation 2018-05; URL https://doi.org/10.1038/s41439-018-0004-z) (sato2018noveltfap2amutation pages 1-3).

1.2 Key identifiers

• OMIM (disease): 113620 (milunsky2008tfap2amutationsresult pages 1-2, sato2018noveltfap2amutation pages 1-3, reiber2010additionalclinicaland pages 1-2)
• OMIM (gene): TFAP2A = 107580 (sato2018noveltfap2amutation pages 1-3, haldemanenglert2025branchiooculofacialsyndrome pages 1-4)
• Gene locus: TFAP2A at 6p24.3 (curated summary) (haldemanenglert2025branchiooculofacialsyndrome pages 11-14). Older primary papers also report mapping as 6p21.3 (reiber2010additionalclinicaland pages 1-2).
• Orphanet / ICD-10 / ICD-11 / MeSH: Not present in the retrieved full-text excerpts; these require direct lookup in Orphanet/ICD/MeSH resources.

1.3 Synonyms / alternative names

• Branchio-oculo-facial syndrome (BOFS)
• Branchiooculofacial syndrome
• BOF syndrome (haldemanenglert2025branchiooculofacialsyndrome pages 1-4)

1.4 Evidence source type

The BOFS knowledge here is derived mainly from aggregated disease-level resources (GeneReviews-style summary excerpts), cohort studies, and case reports, rather than EHR-derived cohorts (haldemanenglert2025branchiooculofacialsyndrome pages 1-4, milunsky2011genotype–phenotypeanalysisof pages 1-2).

2. Etiology

2.1 Disease causal factors

Primary cause: heterozygous pathogenic variants affecting TFAP2A (autosomal dominant), including coding variants, deletions/duplications, mosaicism, and regulatory structural variants that disrupt TFAP2A enhancer contacts (milunsky2008tfap2amutationsresult pages 1-2, milunsky2011genotype–phenotypeanalysisof pages 1-2, shi2023structuralvariantsinvolved pages 1-2).

Direct human genetic evidence for causality includes discovery of a 3.2 Mb deletion including TFAP2A and multiple de novo TFAP2A missense variants in BOFS patients (AJHG 2008-05; URL https://doi.org/10.1016/j.ajhg.2008.03.005) (milunsky2008tfap2amutationsresult pages 1-2).

2.2 Risk factors

• Genetic risk: having a TFAP2A pathogenic variant (autosomal dominant transmission). Approximately 40%–50% of diagnosed individuals have an affected parent and 50%–60% have de novo TFAP2A pathogenic variants (haldemanenglert2025branchiooculofacialsyndrome pages 11-14).
• Environmental risk factors: none were identified in the retrieved evidence; BOFS is primarily genetic (haldemanenglert2025branchiooculofacialsyndrome pages 1-4, min2020aheterozygousnovel pages 1-2).

2.3 Protective factors

No protective genetic or environmental factors were identified in the available evidence.

2.4 Gene–environment interactions

No gene–environment interaction evidence was identified in the retrieved texts.

3. Phenotypes

3.1 Core phenotype domains

BOFS is defined by three major domains: branchial defects, ocular anomalies, and craniofacial anomalies (notably cleft lip/microform cleft) (stoetzel2009confirmationoftfap2a pages 1-2, min2020aheterozygousnovel pages 1-2).

3.2 Phenotype frequencies (recent aggregated estimates)

A curated summary incorporating a large ophthalmic review (172 individuals) reports approximate frequencies: - Cervical cutaneous defects: ~90% - Infra-/supra-auricular defects: ~60% - Cleft lip / microform cleft lip (with or without cleft palate): 99% (no isolated cleft palate reported) - Hearing loss: ~70% - Renal structural anomalies: ~35% - Thymic anomalies: ~35% - Ocular findings (172-case review): nasolacrimal duct stenosis 57%, coloboma 46%, anophthalmia/microphthalmia 37%, cataract 16%, strabismus 14%, myopia 12% (haldemanenglert2025branchiooculofacialsyndrome pages 4-7).

Additional tabulated frequencies from older clinical compilation include: - Ectodermal anomalies: 37/62 (60%) - Dental anomalies: 23/55 (42%) - Prematurely gray hair: 20/53 (38%) - Malformed middle/inner ear: 10/27 (37%) - Kidney anomaly: 17/48 (35%) - Growth retardation: 18/62 (29%) - Congenital heart disease: 3/37 (8%) - Intellectual disability/mental retardation: 8/56 (14%) (lugli2015earlydiagnosisof pages 4-4).

3.3 Onset, severity, progression

• Typical onset: congenital; often clinically diagnosable in infancy (haldemanenglert2025branchiooculofacialsyndrome pages 4-7, min2020aheterozygousnovel pages 1-2).
• Severity: highly variable, including “non-classical” ocular-predominant presentations (ng2019tfap2amutationin pages 4-4).
• Course: generally lifelong congenital anomalies; progression is not a defining feature, but functional outcomes depend on vision/hearing and craniofacial complications (thomeer2010clinicalpresentationand pages 4-6, haldemanenglert2025branchiooculofacialsyndrome pages 9-11).

3.4 Quality-of-life (QoL) impacts

Direct QoL instrument data (EQ-5D/SF-36) were not identified. However, the functional burden is implied by frequent visual and hearing handicaps and by explicit psychosocial surveillance recommendations: “Monitor for signs of low self-esteem & other psychologic issues.” (haldemanenglert2025branchiooculofacialsyndrome pages 11-14, milunsky2011genotype–phenotypeanalysisof pages 7-7).

3.5 Suggested HPO terms (examples)

Representative HPO mappings (non-exhaustive; based on described phenotypes in retrieved evidence): - Branchial/cutaneous: Branchial fistula (HP:0009795); Cervical sinus (HP:0009796); Aplasia cutis congenita (if present); Ectopic thymus (no single canonical HP term; map via “Thymus hypoplasia/abnormality” as appropriate) (thomeer2010clinicalpresentationand pages 4-6, lugli2015earlydiagnosisof pages 1-3). - Craniofacial: Cleft lip (HP:0000204); Cleft palate (HP:0000175); Broad nasal bridge (HP:0000431); Hypertelorism (HP:0000316); Telecanthus (HP:0000506); Dolichocephaly (HP:0000268) (haldemanenglert2025branchiooculofacialsyndrome pages 4-7, min2020aheterozygousnovel pages 1-2). - Ocular: Microphthalmia (HP:0000568); Anophthalmia (HP:0000528); Coloboma (HP:0000589); Congenital cataract (HP:0000519); Strabismus (HP:0000486); Nasolacrimal duct obstruction (HP:0000579) (haldemanenglert2025branchiooculofacialsyndrome pages 4-7, min2020aheterozygousnovel pages 1-2). - Auditory/temporal bone: Hearing impairment (HP:0000365); Conductive hearing impairment (HP:0000405); Sensorineural hearing impairment (HP:0000407); Abnormality of the ossicles (HP:0000380) (thomeer2010clinicalpresentationand pages 4-6). - Renal: Renal agenesis (HP:0000104); Multicystic dysplastic kidney (HP:0000003); Vesicoureteral reflux (HP:0000076) (milunsky2011genotype–phenotypeanalysisof pages 9-10). - Ectodermal: Premature graying of hair (HP:0002216); Dental anomalies (HP:0000164); Nail dystrophy (HP:0002164) (lugli2015earlydiagnosisof pages 4-4).

4. Genetic / Molecular Information

4.1 Causal gene(s)

• TFAP2A (Transcription Factor AP-2 Alpha), OMIM 107580; BOFS OMIM 113620 (sato2018noveltfap2amutation pages 1-3, haldemanenglert2025branchiooculofacialsyndrome pages 1-4).

4.2 Inheritance, penetrance, expressivity

• Autosomal dominant (haldemanenglert2025branchiooculofacialsyndrome pages 1-4, haldemanenglert2025branchiooculofacialsyndrome pages 11-14).
• De novo rate: approximately 50%–60% de novo TFAP2A pathogenic variants; ~40%–50% inherited from an affected parent (haldemanenglert2025branchiooculofacialsyndrome pages 11-14).
• Penetrance: described as almost complete, with significant intrafamilial variability (haldemanenglert2025branchiooculofacialsyndrome pages 11-14, haldemanenglert2025branchiooculofacialsyndrome pages 4-7).
• Mosaicism: parental somatic/germline mosaicism is specifically highlighted as a recurrence-risk consideration (haldemanenglert2025branchiooculofacialsyndrome pages 11-14).

4.3 Pathogenic variant spectrum (by class)

Reported pathogenic mechanisms include: - Missense (dominant class; hotspot in exons 4–5) (milunsky2011genotype–phenotypeanalysisof pages 1-2, milunsky2011genotype–phenotypeanalysisof pages 6-7) - Nonsense (example: c.912C>A, p.Cys304) (Front Pediatr 2020-07; URL https://doi.org/10.3389/fped.2020.00380) (min2020aheterozygousnovel pages 1-2) - Frameshift / small indels (reported in curated summary) (haldemanenglert2025branchiooculofacialsyndrome pages 4-7) - Splice-altering variants (including predicted creation of a new splice acceptor in one report) (reiber2010additionalclinicaland pages 3-5) - Large deletions/CNVs including a 3.2 Mb deletion encompassing TFAP2A (milunsky2008tfap2amutationsresult pages 1-2, milunsky2011genotype–phenotypeanalysisof pages 1-2) - Regulatory structural variants*: an inversion disconnecting TFAP2A from enhancers (cited as causative) (shi2023structuralvariantsinvolved pages 1-2)

4.4 Hotspots and recurrent variants

A large cohort identified a strong hotspot in conserved exons 4–5 with multiple recurrent amino acid substitutions, including R254 changes, R237 changes, E242K, G251E, R255G, and A256V (milunsky2011genotype–phenotypeanalysisof pages 6-7). A separate study also reports c.763A>G (p.Arg255Gly) as a probable mutational hotspot (reiber2010additionalclinicaland pages 1-2).

4.5 Allele frequency / population data

Population allele frequencies (e.g., gnomAD) and ClinVar aggregate counts were not available in the retrieved full-text excerpts and cannot be reliably reported here.

5. Environmental Information

No environmental, lifestyle, or infectious contributors have been reported in the retrieved sources; BOFS is best supported as a genetic developmental disorder (haldemanenglert2025branchiooculofacialsyndrome pages 1-4, min2020aheterozygousnovel pages 1-2).

6. Mechanism / Pathophysiology

6.1 Current mechanistic model (integrating human genetics + developmental biology)

Upstream trigger: heterozygous TFAP2A loss-of-function or impaired regulation (coding variant, deletion, mosaicism, or enhancer disconnection) (milunsky2008tfap2amutationsresult pages 1-2, shi2023structuralvariantsinvolved pages 1-2).

Molecular role of TFAP2A: TFAP2A is a retinoic acid–responsive AP-2 family transcription factor, expressed in premigratory and migratory neural crest cells, regulating gene expression during embryogenesis of the eye, ear, face, limbs, body wall, and neural tube; it is also “required for early morphogenesis of the lens” (haldemanenglert2025branchiooculofacialsyndrome pages 11-14).

Downstream developmental disruption: 2024 mechanistic work shows TFAP2 paralogs regulate cranial neural crest midfacial development partly by directly activating ALX transcription factor genes (Alx1/Alx3/Alx4) (Development 2024-01; URL https://doi.org/10.1242/dev.202095). Loss of TFAP2 function reduces Alx transcripts and dysregulates broader midface gene regulatory network components; these changes are linked to midfacial clefts and craniofacial skeletal abnormalities in mouse and zebrafish models (nguyen2024tfap2paralogsregulate pages 1-3, nguyen2024tfap2paralogsregulate pages 7-9).

Regulatory SV mechanism: A high-quality 2023 structural variation paper explicitly notes that “an inversion disconnecting TFAP2A from its enhancers causes branchiooculofacial syndrome,” supporting that disrupted long-range enhancer–promoter regulation can phenocopy coding loss-of-function in BOFS (Nature Communications 2023-12; URL https://doi.org/10.1038/s41467-023-44034-z) (shi2023structuralvariantsinvolved pages 1-2).

6.2 Suggested ontology terms

GO Biological Process (examples): - Neural crest cell development / differentiation / migration - Craniofacial morphogenesis - Eye development; lens morphogenesis - Regulation of transcription (DNA-templated)

Cell Ontology (CL) (examples): - Cranial neural crest cell (CNCC)

UBERON (examples): - Pharyngeal arch derivatives (first and second pharyngeal arches) - Eye, lens, inner ear, midface

Evidence types: human genetic causality (milunsky2008tfap2amutationsresult pages 1-2); animal model mechanistic pathway mapping (mouse + zebrafish) (nguyen2024tfap2paralogsregulate pages 1-3, nguyen2024tfap2paralogsregulate pages 7-9).

7. Anatomical Structures Affected

7.1 Organ/system level

Primary systems: - Craniofacial/orofacial (cleft lip ± cleft palate; characteristic facial morphology) (haldemanenglert2025branchiooculofacialsyndrome pages 4-7, min2020aheterozygousnovel pages 1-2) - Ocular (microphthalmia/anophthalmia, coloboma, cataract, strabismus, nasolacrimal duct obstruction) (haldemanenglert2025branchiooculofacialsyndrome pages 4-7) - Auditory/temporal bone (hearing loss; middle/inner ear malformations; external canal anomalies) (thomeer2010clinicalpresentationand pages 4-6, lugli2015earlydiagnosisof pages 4-4) Secondary/variable: - Renal anomalies (~35%) (milunsky2011genotype–phenotypeanalysisof pages 9-10, haldemanenglert2025branchiooculofacialsyndrome pages 4-7) - Thymic anomalies (~35%) (haldemanenglert2025branchiooculofacialsyndrome pages 4-7) - Ectodermal appendages (hair, teeth, nails) (lugli2015earlydiagnosisof pages 4-4)

8. Temporal Development

• Onset: congenital; diagnosis often made in infancy (haldemanenglert2025branchiooculofacialsyndrome pages 4-7, min2020aheterozygousnovel pages 1-2).
• Progression: primarily structural/developmental anomalies; long-term course depends on corrective surgeries and sensory impairment management. No staging system is established in retrieved sources.

9. Inheritance and Population

9.1 Inheritance

• Autosomal dominant; 50% recurrence risk to offspring of an affected individual (haldemanenglert2025branchiooculofacialsyndrome pages 11-14).

9.2 Epidemiology

Robust prevalence/incidence statistics were not found in the retrieved evidence. Case-count statements indicate rarity, with older and newer summaries noting roughly ~50 cases in older literature and <150 well-described cases in later reports/curated summaries (reiber2010additionalclinicaland pages 1-2, min2020aheterozygousnovel pages 1-2).

10. Diagnostics

10.1 Clinical diagnostic concept

Clinical diagnosis may be made by recognizing the triad of branchial, ocular, and craniofacial features; atypical presentations exist and motivate molecular confirmation (min2020aheterozygousnovel pages 1-2, lugli2015earlydiagnosisof pages 1-3).

10.2 Genetic testing (recommended approach)

A curated diagnostic workflow recommends: 1) TFAP2A sequence analysis first, and 2) if negative, gene-targeted deletion/duplication analysis to detect exon- or whole-gene CNVs (haldemanenglert2025branchiooculofacialsyndrome pages 1-4).

Testing options include single-gene testing, multigene panels, and exome/genome sequencing (haldemanenglert2025branchiooculofacialsyndrome pages 1-4).

10.3 Recent diagnostic yield / real-world implementation (2024 priority)

In an EJHG 2024 study of individuals with orofacial clefts plus microphthalmia/anophthalmia/coloboma (OC+MAC), WES provided a conclusive diagnosis in 6/17 (35.29%), including a TFAP2A/BOFS diagnosis, while CMA detected no pathogenic/likely pathogenic CNVs (Publication date: 2024-11; URL https://doi.org/10.1038/s41431-023-01488-5) (tacla2024molecularinvestigationin pages 1-2).

11. Outcome / Prognosis

• Life expectancy/survival: not reported in the retrieved evidence.
• Morbidity drivers: visual impairment, hearing loss, and complications of craniofacial anomalies (e.g., cleft-related feeding/speech issues; branchial sinus complications) (thomeer2010clinicalpresentationand pages 4-6, haldemanenglert2025branchiooculofacialsyndrome pages 9-11).
• Neurodevelopment: typically normal; intellectual disability is uncommon but reported (~14% in an older compilation) (lugli2015earlydiagnosisof pages 4-4, haldemanenglert2025branchiooculofacialsyndrome pages 4-7).
• Cancer risk: evidence is limited. One cohort excerpt notes a single affected individual with medulloblastoma, without establishing a clear predisposition; curated text states “The role of cancer surveillance is not established.” (milunsky2011genotype–phenotypeanalysisof pages 7-9, haldemanenglert2025branchiooculofacialsyndrome pages 9-11).

12. Treatment

No disease-modifying pharmacologic therapy is established in the retrieved evidence; management is supportive and surgical.

12.1 Surgical / interventional and supportive care

A curated summary recommends that affected children be managed by a multispecialty craniofacial team and notes interventions including: - Nasolacrimal duct surgery for stenosis/atresia - Cleft lip repair by experienced pediatric plastic surgeons - Orbital conformer for anophthalmia/severe microphthalmia - Standard-of-care management for hearing loss, renal malformations, dental manifestations, congenital heart defects (haldemanenglert2025branchiooculofacialsyndrome pages 1-4, haldemanenglert2025branchiooculofacialsyndrome pages 9-11).

A detailed otologic case series documents real-world implementation for conductive hearing loss: CT temporal bone imaging; canal/middle ear surgeries; and bone-anchored hearing aid (BAHA) implantation with postoperative audiometric improvement (thomeer2010clinicalpresentationand pages 4-6).

12.2 Suggested MAXO terms (examples)

• Cleft lip repair (surgical repair)
• Nasolacrimal duct surgery
• Hearing amplification / bone-anchored hearing device placement
• Multidisciplinary craniofacial care
• Genetic counseling

13. Prevention

BOFS prevention is primarily genetic and surveillance-based: - Primary prevention / reproductive options: prenatal and preimplantation genetic testing once a familial TFAP2A pathogenic variant is identified (haldemanenglert2025branchiooculofacialsyndrome pages 11-14, haldemanenglert2025branchiooculofacialsyndrome pages 1-4). - Secondary prevention: evaluation of at-risk relatives and surveillance to detect treatable complications (hearing, vision, renal) (haldemanenglert2025branchiooculofacialsyndrome pages 11-14, haldemanenglert2025branchiooculofacialsyndrome pages 9-11). - Tertiary prevention: timely surgical correction and supportive therapies to minimize disability (thomeer2010clinicalpresentationand pages 4-6, haldemanenglert2025branchiooculofacialsyndrome pages 1-4).

14. Other Species / Natural Disease

No naturally occurring veterinary BOFS analogs were identified in the retrieved evidence.

15. Model Organisms

Recent mechanistic work uses mouse and zebrafish models to study TFAP2 function in cranial neural crest and midfacial development, demonstrating clefting and dysregulated ALX pathway activity after Tfap2 perturbation (nguyen2024tfap2paralogsregulate pages 1-3, nguyen2024tfap2paralogsregulate pages 7-9).

Expert synthesis / analysis (authoritative interpretation)

1) BOFS is best conceptualized as a neural-crest–related developmental disorder (neurocristopathy) driven by haploinsufficiency or functional impairment of TFAP2A, with broad effects on gene regulatory networks controlling facial, ocular, and ear morphogenesis (haldemanenglert2025branchiooculofacialsyndrome pages 11-14, nguyen2024tfap2paralogsregulate pages 1-3). 2) Variant interpretation and test selection must explicitly account for both coding and non-coding mechanisms. In addition to recurrent missense hotspots (exons 4–5), large deletions and enhancer-disconnecting inversions can cause BOFS; therefore, negative sequencing should prompt CNV/structural variant evaluation when suspicion remains high (milunsky2011genotype–phenotypeanalysisof pages 6-7, milunsky2008tfap2amutationsresult pages 1-2, shi2023structuralvariantsinvolved pages 1-2). 3) Real-world practice increasingly relies on exome sequencing and integrated craniofacial care, supported by a 2024 cohort demonstrating meaningful WES diagnostic yield in complex cranio-ocular phenotypes that included BOFS (tacla2024molecularinvestigationin pages 1-2) and by detailed otologic management examples showing benefit of advanced hearing interventions (thomeer2010clinicalpresentationand pages 4-6).

Summary Table (for knowledge base ingestion)

Table: This table condenses the main disease-knowledge-base fields for Branchio-oculo-facial syndrome, including identifiers, phenotype frequencies, TFAP2A variant mechanisms, testing workflow, and practical management points. It emphasizes recent diagnostic and mechanistic evidence while anchoring claims to primary BOFS literature and curated summaries.

Key References (publication dates and URLs)

(These are the most central sources used in this report; additional sources are embedded in citations above.) - Milunsky JM et al. Am J Hum Genet. 2008-05. “TFAP2A mutations result in branchio-oculo-facial syndrome.” https://doi.org/10.1016/j.ajhg.2008.03.005 (milunsky2008tfap2amutationsresult pages 1-2) - Milunsky JM et al. Am J Med Genet A. 2011-01. “Genotype–phenotype analysis of the branchio-oculo-facial syndrome.” https://doi.org/10.1002/ajmg.a.33783 (milunsky2011genotype–phenotypeanalysisof pages 1-2, milunsky2011genotype–phenotypeanalysisof pages 9-10) - Tacla MA et al. Eur J Hum Genet. 2024-11. “Molecular investigation in individuals with orofacial clefts and microphthalmia-anophthalmia-coloboma spectrum.” https://doi.org/10.1038/s41431-023-01488-5 (tacla2024molecularinvestigationin pages 1-2) - Nguyen TT et al. Development. 2024-01. “TFAP2 paralogs regulate midfacial development in part through a conserved ALX genetic pathway.” https://doi.org/10.1242/dev.202095 (nguyen2024tfap2paralogsregulate pages 1-3, nguyen2024tfap2paralogsregulate pages 7-9) - Shi J et al. Nat Commun. 2023-12. “Structural variants involved in high-altitude adaptation…” (includes BOFS regulatory SV statement). https://doi.org/10.1038/s41467-023-44034-z (shi2023structuralvariantsinvolved pages 1-2) - Thomeer HGXM et al. Ann Otol Rhinol Laryngol. 2010-12. “Clinical Presentation…hearing impairment…” https://doi.org/10.1177/000348941011901204 (thomeer2010clinicalpresentationand pages 4-6)

References

1. (sato2018noveltfap2amutation pages 1-3): Taisuke Sato, Osamu Samura, Noriko Kato, Kosuke Taniguchi, Ken Takahashi, Yuki Ito, Hiroaki Aoki, Masahisa Kobayashi, Ohsuke Migita, Aikou Okamoto, and Kenichiro Hata. Novel tfap2a mutation in a japanese family with branchio-oculo-facial syndrome. Human Genome Variation, May 2018. URL: https://doi.org/10.1038/s41439-018-0004-z, doi:10.1038/s41439-018-0004-z. This article has 19 citations.

2. (haldemanenglert2025branchiooculofacialsyndrome pages 1-4): CR Haldeman-Englert and AE Lin. Branchiooculofacial syndrome. Unknown journal, 2025.

3. (min2020aheterozygousnovel pages 1-2): Jie Min, Bing Mao, Yong Wang, Xuelian He, Shuyang Gao, and Hairong Wang. A heterozygous novel mutation in tfap2a gene causes atypical branchio-oculo-facial syndrome with isolated coloboma of choroid: a case report. Frontiers in Pediatrics, Jul 2020. URL: https://doi.org/10.3389/fped.2020.00380, doi:10.3389/fped.2020.00380. This article has 8 citations.

4. (haldemanenglert2025branchiooculofacialsyndrome pages 4-7): CR Haldeman-Englert and AE Lin. Branchiooculofacial syndrome. Unknown journal, 2025.

5. (milunsky2008tfap2amutationsresult pages 1-2): Jeff M. Milunsky, Tom A. Maher, Geping Zhao, Amy E. Roberts, Heather J. Stalker, Roberto T. Zori, Michelle N. Burch, Michele Clemens, John B. Mulliken, Rosemarie Smith, and Angela E. Lin. Tfap2a mutations result in branchio-oculo-facial syndrome. American journal of human genetics, 82 5:1171-7, May 2008. URL: https://doi.org/10.1016/j.ajhg.2008.03.005, doi:10.1016/j.ajhg.2008.03.005. This article has 258 citations and is from a highest quality peer-reviewed journal.

6. (reiber2010additionalclinicaland pages 1-2): Judith Reiber, Yves Sznajer, Elena Guillén Posteguillo, Dietmar Müller, Stanislas Lyonnet, Clarisse Baumann, and Walter Just. Additional clinical and molecular analyses of tfap2a in patients with the branchio‐oculo‐facial syndrome. American Journal of Medical Genetics Part A, 152A:994-999, Apr 2010. URL: https://doi.org/10.1002/ajmg.a.33331, doi:10.1002/ajmg.a.33331. This article has 31 citations.

7. (haldemanenglert2025branchiooculofacialsyndrome pages 11-14): CR Haldeman-Englert and AE Lin. Branchiooculofacial syndrome. Unknown journal, 2025.

8. (milunsky2011genotype–phenotypeanalysisof pages 1-2): Jeff M. Milunsky, Tom M. Maher, Geping Zhao, Zhenyuan Wang, John B. Mulliken, David Chitayat, Michele Clemens, Heather J. Stalker, Mislen Bauer, Michele Burch, Sébastien Chénier, Michael L. Cunningham, Arlene V. Drack, Sandra Janssens, Audrey Karlea, Regan Klatt, Usha Kini, Ophir Klein, Augusta M. Lachmeijer, Andre Megarbane, Nancy J. Mendelsohn, Wendy S. Meschino, Geert R. Mortier, Sandhya Parkash, C. Renai Ray, Angharad Roberts, Amy Roberts, Willie Reardon, Rhonda E. Schnur, Rosemarie Smith, Miranda Splitt, Kamer Tezcan, Margo L. Whiteford, Derek A. Wong, Roberto Zori, and Angela E. Lin. Genotype–phenotype analysis of the branchio‐oculo‐facial syndrome. American Journal of Medical Genetics Part A, 155:22-32, Jan 2011. URL: https://doi.org/10.1002/ajmg.a.33783, doi:10.1002/ajmg.a.33783. This article has 81 citations.

9. (shi2023structuralvariantsinvolved pages 1-2): Jinlong Shi, Zhilong Jia, Jinxiu Sun, Xiaoreng Wang, Xiaojing Zhao, Chenghui Zhao, Fan Liang, Xinyu Song, Jiawei Guan, Xue Jia, Jing Yang, Qi Chen, Kang Yu, Qian Jia, Jing Wu, Depeng Wang, Yuhui Xiao, Xiaoman Xu, Yinzhe Liu, Shijing Wu, Qin Zhong, Jue Wu, Saijia Cui, Xiaochen Bo, Zhenzhou Wu, Minsung Park, Manolis Kellis, and Kunlun He. Structural variants involved in high-altitude adaptation detected using single-molecule long-read sequencing. Nature Communications, Dec 2023. URL: https://doi.org/10.1038/s41467-023-44034-z, doi:10.1038/s41467-023-44034-z. This article has 41 citations and is from a highest quality peer-reviewed journal.

10. (stoetzel2009confirmationoftfap2a pages 1-2): C. Stoetzel, S. Riehm, V. B. Greene, V. Pelletier, J. Vigneron, Bruno Leheup, Vincent Marion, Sophie Hellé, Jean-Marc Danse, C. Thibault, Luc Moulinier, F. Veillon, and Hélène Dollfus. Confirmation of tfap2a gene involvement in branchio‐oculo‐facial syndrome (bofs) and report of temporal bone anomalies. American Journal of Medical Genetics Part A, 149A:2141-2146, Oct 2009. URL: https://doi.org/10.1002/ajmg.a.33015, doi:10.1002/ajmg.a.33015. This article has 44 citations.

11. (lugli2015earlydiagnosisof pages 4-4): Licia Lugli, Walter Just, Elisabetta Genovese, Silvia Palma, Fabrizio Ferrari, and Antonio Percesepe. Early diagnosis of branchio-oculo-facial syndrome in a patient with inner ear malformation and mild ocular involvement. Clinical Dysmorphology, 24:17–20, Jan 2015. URL: https://doi.org/10.1097/mcd.0000000000000061, doi:10.1097/mcd.0000000000000061. This article has 1 citations and is from a peer-reviewed journal.

12. (ng2019tfap2amutationin pages 4-4): Pamela Si-Min Ng, Shazia Khan, Jiin Ying Lim, Jasmine Chew-Yin Goh, Grace Xiulin Lin, Heming Wei, Ene Choo Tan, and Saumya Shekhar Jamuar. Tfap2a mutation in a child and mother with predominantly ocular anomalies: non-classical presentation of branchio-oculo-facial syndrome. Clinical Dysmorphology, 28:215-218, Oct 2019. URL: https://doi.org/10.1097/mcd.0000000000000290, doi:10.1097/mcd.0000000000000290. This article has 2 citations and is from a peer-reviewed journal.

13. (thomeer2010clinicalpresentationand pages 4-6): Henricus G. X. M. Thomeer, Tom T. H. Crins, Erik J. Kamsteeg, Wendy Buijsman, Johannes R. M. Cruysberg, Nine V. A. M. Knoers, and W. R. J. Cremers. Clinical presentation and the presence of hearing impairment in branchio-oculo-facial syndrome: a new mutation in the tfap2a gene. Annals of Otology, Rhinology & Laryngology, 119:806-814, Dec 2010. URL: https://doi.org/10.1177/000348941011901204, doi:10.1177/000348941011901204. This article has 12 citations.

14. (haldemanenglert2025branchiooculofacialsyndrome pages 9-11): CR Haldeman-Englert and AE Lin. Branchiooculofacial syndrome. Unknown journal, 2025.

15. (milunsky2011genotype–phenotypeanalysisof pages 7-7): Jeff M. Milunsky, Tom M. Maher, Geping Zhao, Zhenyuan Wang, John B. Mulliken, David Chitayat, Michele Clemens, Heather J. Stalker, Mislen Bauer, Michele Burch, Sébastien Chénier, Michael L. Cunningham, Arlene V. Drack, Sandra Janssens, Audrey Karlea, Regan Klatt, Usha Kini, Ophir Klein, Augusta M. Lachmeijer, Andre Megarbane, Nancy J. Mendelsohn, Wendy S. Meschino, Geert R. Mortier, Sandhya Parkash, C. Renai Ray, Angharad Roberts, Amy Roberts, Willie Reardon, Rhonda E. Schnur, Rosemarie Smith, Miranda Splitt, Kamer Tezcan, Margo L. Whiteford, Derek A. Wong, Roberto Zori, and Angela E. Lin. Genotype–phenotype analysis of the branchio‐oculo‐facial syndrome. American Journal of Medical Genetics Part A, 155:22-32, Jan 2011. URL: https://doi.org/10.1002/ajmg.a.33783, doi:10.1002/ajmg.a.33783. This article has 81 citations.

16. (lugli2015earlydiagnosisof pages 1-3): Licia Lugli, Walter Just, Elisabetta Genovese, Silvia Palma, Fabrizio Ferrari, and Antonio Percesepe. Early diagnosis of branchio-oculo-facial syndrome in a patient with inner ear malformation and mild ocular involvement. Clinical Dysmorphology, 24:17–20, Jan 2015. URL: https://doi.org/10.1097/mcd.0000000000000061, doi:10.1097/mcd.0000000000000061. This article has 1 citations and is from a peer-reviewed journal.

17. (milunsky2011genotype–phenotypeanalysisof pages 9-10): Jeff M. Milunsky, Tom M. Maher, Geping Zhao, Zhenyuan Wang, John B. Mulliken, David Chitayat, Michele Clemens, Heather J. Stalker, Mislen Bauer, Michele Burch, Sébastien Chénier, Michael L. Cunningham, Arlene V. Drack, Sandra Janssens, Audrey Karlea, Regan Klatt, Usha Kini, Ophir Klein, Augusta M. Lachmeijer, Andre Megarbane, Nancy J. Mendelsohn, Wendy S. Meschino, Geert R. Mortier, Sandhya Parkash, C. Renai Ray, Angharad Roberts, Amy Roberts, Willie Reardon, Rhonda E. Schnur, Rosemarie Smith, Miranda Splitt, Kamer Tezcan, Margo L. Whiteford, Derek A. Wong, Roberto Zori, and Angela E. Lin. Genotype–phenotype analysis of the branchio‐oculo‐facial syndrome. American Journal of Medical Genetics Part A, 155:22-32, Jan 2011. URL: https://doi.org/10.1002/ajmg.a.33783, doi:10.1002/ajmg.a.33783. This article has 81 citations.

18. (milunsky2011genotype–phenotypeanalysisof pages 6-7): Jeff M. Milunsky, Tom M. Maher, Geping Zhao, Zhenyuan Wang, John B. Mulliken, David Chitayat, Michele Clemens, Heather J. Stalker, Mislen Bauer, Michele Burch, Sébastien Chénier, Michael L. Cunningham, Arlene V. Drack, Sandra Janssens, Audrey Karlea, Regan Klatt, Usha Kini, Ophir Klein, Augusta M. Lachmeijer, Andre Megarbane, Nancy J. Mendelsohn, Wendy S. Meschino, Geert R. Mortier, Sandhya Parkash, C. Renai Ray, Angharad Roberts, Amy Roberts, Willie Reardon, Rhonda E. Schnur, Rosemarie Smith, Miranda Splitt, Kamer Tezcan, Margo L. Whiteford, Derek A. Wong, Roberto Zori, and Angela E. Lin. Genotype–phenotype analysis of the branchio‐oculo‐facial syndrome. American Journal of Medical Genetics Part A, 155:22-32, Jan 2011. URL: https://doi.org/10.1002/ajmg.a.33783, doi:10.1002/ajmg.a.33783. This article has 81 citations.

19. (reiber2010additionalclinicaland pages 3-5): Judith Reiber, Yves Sznajer, Elena Guillén Posteguillo, Dietmar Müller, Stanislas Lyonnet, Clarisse Baumann, and Walter Just. Additional clinical and molecular analyses of tfap2a in patients with the branchio‐oculo‐facial syndrome. American Journal of Medical Genetics Part A, 152A:994-999, Apr 2010. URL: https://doi.org/10.1002/ajmg.a.33331, doi:10.1002/ajmg.a.33331. This article has 31 citations.

20. (nguyen2024tfap2paralogsregulate pages 1-3): Timothy T. Nguyen, Jennyfer M. Mitchell, Michaela D. Kiel, Colin P. Kenny, Hong Li, Kenneth L. Jones, Robert A. Cornell, Trevor J. Williams, James T. Nichols, and Eric Van Otterloo. Tfap2 paralogs regulate midfacial development in part through a conserved alx genetic pathway. Development, Jan 2024. URL: https://doi.org/10.1242/dev.202095, doi:10.1242/dev.202095. This article has 17 citations and is from a domain leading peer-reviewed journal.

21. (nguyen2024tfap2paralogsregulate pages 7-9): Timothy T. Nguyen, Jennyfer M. Mitchell, Michaela D. Kiel, Colin P. Kenny, Hong Li, Kenneth L. Jones, Robert A. Cornell, Trevor J. Williams, James T. Nichols, and Eric Van Otterloo. Tfap2 paralogs regulate midfacial development in part through a conserved alx genetic pathway. Development, Jan 2024. URL: https://doi.org/10.1242/dev.202095, doi:10.1242/dev.202095. This article has 17 citations and is from a domain leading peer-reviewed journal.

22. (tacla2024molecularinvestigationin pages 1-2): Milena Atique Tacla, Matheus de Mello Copelli, Eleonore Pairet, Isabella Lopes Monlleó, Erlane Marques Ribeiro, Elaine Lustosa Mendes, Raphaël Helaers, Tarsis Paiva Vieira, Miikka Vikkula, and Vera Lúcia Gil-da-Silva-Lopes. Molecular investigation in individuals with orofacial clefts and microphthalmia-anophthalmia-coloboma spectrum. European journal of human genetics : EJHG, 32:1257-1266, Nov 2024. URL: https://doi.org/10.1038/s41431-023-01488-5, doi:10.1038/s41431-023-01488-5. This article has 5 citations.

23. (milunsky2011genotype–phenotypeanalysisof pages 7-9): Jeff M. Milunsky, Tom M. Maher, Geping Zhao, Zhenyuan Wang, John B. Mulliken, David Chitayat, Michele Clemens, Heather J. Stalker, Mislen Bauer, Michele Burch, Sébastien Chénier, Michael L. Cunningham, Arlene V. Drack, Sandra Janssens, Audrey Karlea, Regan Klatt, Usha Kini, Ophir Klein, Augusta M. Lachmeijer, Andre Megarbane, Nancy J. Mendelsohn, Wendy S. Meschino, Geert R. Mortier, Sandhya Parkash, C. Renai Ray, Angharad Roberts, Amy Roberts, Willie Reardon, Rhonda E. Schnur, Rosemarie Smith, Miranda Splitt, Kamer Tezcan, Margo L. Whiteford, Derek A. Wong, Roberto Zori, and Angela E. Lin. Genotype–phenotype analysis of the branchio‐oculo‐facial syndrome. American Journal of Medical Genetics Part A, 155:22-32, Jan 2011. URL: https://doi.org/10.1002/ajmg.a.33783, doi:10.1002/ajmg.a.33783. This article has 81 citations.

24. (haldemanenglert2025branchiooculofacialsyndrome pages 7-9): CR Haldeman-Englert and AE Lin. Branchiooculofacial syndrome. Unknown journal, 2025.

Artifacts

• Edison artifact artifact-00